Regenxbio Inc (NASDAQ:RGNX) gets downgraded to Buy by Bank of America

ME Staff
-
0

Analyst Ratings For Regenxbio Inc (NASDAQ:RGNX)

Today, Regenxbio Inc (NASDAQ:RGNX) stock was downgraded by Bank of America from Buy to Neutral.

There are 0 sell ratings, 2 hold ratings, 5 buy ratings, 0 strong buy ratings on the stock.

The current consensus rating on Regenxbio Inc (NASDAQ:RGNX) is Buy with a consensus target price of $62.4286 per share, a potential 18.50% downside.

Some recent analyst ratings include

  • 7/23/2018-Bank of America was Downgraded by analysts at Bank of America from a “Buy ” rating to a ” Neutral” rating. They now have a N/A price target on the stock.
  • 6/25/2018-Raymond James Reiterated Rating of Buy.
  • 5/9/2018-Barclays Reiterated Rating of Overweight .
  • 2/12/2018-Mizuho initiated coverage with a Neutral rating.
  • 8/16/2017-Evercore ISI initiated coverage with a Outperform rating.

Recent Insider Trading Activity For Regenxbio Inc (NASDAQ:RGNX)
Regenxbio Inc (NASDAQ:RGNX) has insider ownership of 16.90% and institutional ownership of 70.08%.

  • On 7/16/2018 Vittal Vasista, CFO, sold 7,500 with an average share price of $75.54 per share and the total transaction amounting to $566,550.00.
  • On 6/20/2018 Kenneth T Mills, Insider, sold 5,000 with an average share price of $66.20 per share and the total transaction amounting to $331,000.00.
  • On 6/18/2018 Patrick J Christmas, SVP, sold 5,000 with an average share price of $56.78 per share and the total transaction amounting to $283,900.00.
  • On 6/15/2018 Vittal Vasista, CFO, sold 7,500 with an average share price of $56.61 per share and the total transaction amounting to $424,575.00.
  • On 6/5/2018 Donald J Hayden Jr, Director, sold 15,000 with an average share price of $55.01 per share and the total transaction amounting to $825,150.00.
  • On 6/1/2018 Donald J Hayden Jr, Director, sold 100 with an average share price of $55.00 per share and the total transaction amounting to $5,500.00.
  • On 5/21/2018 Kenneth T Mills, Insider, sold 10,000 with an average share price of $47.05 per share and the total transaction amounting to $470,500.00.

About Regenxbio Inc (NASDAQ:RGNX)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Recent Trading Activity for Regenxbio Inc (NASDAQ:RGNX)
Shares of Regenxbio Inc closed the previous trading session at 76.60 −2.75 3.47% with 79.9 shares trading hands.